Modalis Therapeutics Prioritizes Key Program
Company Announcements

Modalis Therapeutics Prioritizes Key Program

Modalis Therapeutics Corporation (JP:4883) has released an update.

Modalis Therapeutics Corporation has announced a strategic plan to prioritize their leading AAV therapeutics program and restructure their U.S. subsidiary, leading to a reduction of operating expenses by downsizing personnel. The company is focusing on obtaining IND clearance for their MDL-101 clinical trial and expects these changes to reduce expenses by 35-40 million yen for the fiscal year ending December 31, 2024.

For further insights into JP:4883 stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App